Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 2Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 6Dexamethasone 5fludarabine 4Bortezomib 468Ga-pentixafor 4Melphalan 3Lenalidomide 3Granulocyte Colony-Stimulating Factor 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Filgrastim 2tocilizumab 1ruxolitinib 1pomalidomide 1methyl prednisolonate 1ioversol 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1daratumumab 1carfilzomib 1blinatumomab 1Thalidomide 1Tacrolimus 1Simvastatin 1Prochlorperazine 1Pemetrexed 1Ondansetron 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Multiple Myeloma × Dasatinib × Clear all
NCT04603872 2020-10-28

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Zhejiang University

Phase EARLY_PHASE1 Recruiting
120 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡